Wolfe Research cuts ResMed stock price target on growth outlook By Investing.com

Wolfe Research cut ResMed’s price target to $180 from $230 and kept an Underperform rating, implying downside from the current $213.81 share price. The firm sees 6% to 7% organic growth and values the stock at 15x next-twelve-month EPS of about $11.90, below the market’s current 21.17 P/E. ResMed recently beat Q3 EPS expectations at $2.86 vs. $2.81, but revenue missed slightly at $1.43 billion vs. $1.42 billion, leaving the stock near its 52-week low.

Analysis

The key issue is not one downgrade, but the direction of travel in the valuation framework: when a subsector’s growth-to-multiple relationship compresses, high-quality compounders lose their scarcity premium even if fundamentals remain intact. For RMD, that means the market is increasingly paying up for near-term predictability only if growth stays in the upper single digits; any deceleration or evidence of saturation in the core sleep-apnea franchise can trigger multiple air pockets well before earnings estimates are cut.

Second-order, this is a signal for the broader med-tech basket. If investors continue rotating from duration-like healthcare compounders into cheaper cyclicals or defensives with clearer reacceleration, large-cap med-tech leaders with premium valuations can underperform despite stable execution. That creates a relative-value setup where the best operators are still vulnerable if they are owned as quality bonds rather than operating businesses.

The near-term catalyst path is asymmetric: the next 1-2 earnings prints matter more than the full-year guide because the stock is already trading close to technical support, so downside can accelerate if sentiment shifts from “mixed quarter” to “multiple compression story.” The contrarian case is that the market may be overreacting to a sector-wide rerating; if ResMed can sustain mid-single-digit organic growth with margin durability, the stock can re-rate back toward a premium multiple, but that likely requires clean execution plus no further analyst target cuts.

For competitors, this pressure can indirectly benefit lower-multiple med-tech names and adjacent healthcare services where growth is less visible but expectations are easier to clear. Supply-chain effects are limited, but any softness in demand assumptions for home respiratory devices would likely hit channel inventory and distributor ordering before showing up in top-line data, creating a lagged downside risk over the next 1-2 quarters.

Key Decisions for Investors

• Short RMD on rallies above the current level with a 1-3 month horizon; use 52-week-low proximity as a technical trigger because downside can accelerate if the market reprices the stock from quality compounder to ex-growth med-tech.
• Pair trade: long a lower-multiple, execution-stable med-tech name versus short RMD over the next 2-4 months to isolate the valuation compression theme and reduce market beta.
• Avoid adding to long-duration healthcare compounders until the next earnings cycle confirms organic growth reacceleration; the risk/reward is poor if the sector multiple continues to compress by another 1-2 turns.
• For options, consider put spreads in RMD with 1-2 quarter expiry to express downside from another analyst reset while capping premium spend; the trade works best if guidance momentum weakens again.
• Set a watchlist trigger for a reclaim of the prior trading range on volume before covering shorts; absent that, rallies likely remain sellable while sector sentiment stays defensive.